Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
32 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
IgY |
Immunoglobulin in chicken egg yolk |
|
|
|
Horse |
Model animal for immunotherapy (passive acquired immunity) |
|
|
|
Black widow spider bite, snake bite |
Disease: horse antivenin |
|
|
|
Botulism, diptheria |
Disease: horse antitoxin |
|
|
|
Hepatitis A & B; measles; rabies; tetanus |
Disease: pooled human immune gamma globulin |
|
|
|
Respiratory disease |
Disease: monoclonal anti-RSV |
|
|
|
1. Horse innoculated with prefusion spike protein 2. Hyperimmune globulins are collected and used for immunotherapy |
Immunotherapy steps (COVID19) |
|
|
|
Anti-prefusion spike (more neutralizing) |
Importanceof using pre-fusion spike as immunogen |
Sars cov 2 changes conformation to allow membrane fusion |
|
|
1. Model is innoculated with antigen, spleen cells are collected 2. Myeloma cell line and spleen cells (#1) are frown in medium 3. Hybrid cells are selected and grown 4. Hybridomas proliferate and screened for desired antibody 5. Chosen hybridoma is used for mass production |
Monoclonal antibody process |
|
|
|
1. Animal is innoculated 2. B cells create polyclonal antibody 3. Antiserum is collected |
Polyclonal antibody process |
|
|
|
Monoclonal |
M vs P: > cost |
|
|
|
Monoclonal |
M vs P: > production time |
|
|
|
Monoclonal |
M vs P: > specificity |
|
|
|
Polyclonal |
M vs P: > epitopes recognized |
|
|
|
Polyclonal |
M vs P: > variation of composition |
|
|
|
Adequate levels of antibody, population of memory cells |
2 goals of active acquired immunity |
|
|
|
High blood titer of antibody |
Requirement for polio immunity |
|
|
|
Macrophage-activating cell mediated immunity (CTC) |
Requirement for mycobacterial disease immunity |
|
|
|
Antibodies in gut lumen |
Requirement for cholera immunity |
Inhibits adherance of vibrio cholerae to intestinal wall |
|
|
Effectiveness |
Consideration for successful aai: evoke protective levels of immunity at appropriate site, of relevant nature (type of immune cell), and adequate duration |
|
|
|
Availability |
Consideration for successful aai: readily culturednin bulk; accessible source of subunit |
|
|
|
Stability |
Consideration for successful aai: survive climatic conditions |
|
|
|
Cheapness |
Consideration for successful aai: no country left behind |
|
|
|
Safety |
Consideration for successful aai: eliminate any other pathogenicity |
|
|
|
Live vaccine |
1 |
|
|
Live attenuated vaccines |
11 |
|
|
Killed inactivated |
8 |
|
|
Diptheria; tetanus |
Toxoids vaccine |
2 |
|
|
Hepatitis B vaccine |
Recombinant vaccine |
1 |
|
|
Cellular fraction vaccines |
3; part of whole pathogen |
|
|
Adjuvant |
Essential fpr enhacing and directing the adaptive immune response tp vaccine antigens |
|
|
|
B & T cellls |
Lymphocytes that mediate adaptive mune response |
|
